Who are AbCellera Biologics's customers? Who does AbCellera Biologics earn revenue from?

Revenue comes from counterparties including Pharma (Lilly · Jazz · royalties), Milestones · royalties (104 programs). Full sourced list: valuechain.wiki/abcellera/customers.md

Who does AbCellera Biologics pay? Who are its key suppliers?

Costs flow to Wet lab · sequencing · clinical (undisclosed) among others. Full sourced list: valuechain.wiki/abcellera/suppliers.md

How does the street rate AbCellera Biologics? What are the price targets?

Broker consensus on file: Buy 3 / Hold 0. Details: valuechain.wiki/abcellera/consensus.md

NASDAQ · AI antibody discovery · pharma partnerships

AbCellera Biologics

An AI antibody-discovery firm. It runs 104 partner programs with Eli Lilly, Biogen, AbbVie, Regeneron and Jazz, with 19 molecules in the clinic, earning milestones and royalties. 2025 revenue ~$33.7M, $700M liquidity. An AI-platform antibody (ABCL635) reached Phase 2. A node selling discovery to pharma.

ABCL Updated Jul 12, 2026 3 AI consumers

Annual return · 2026-07-10'22-29.2%'23-43.6%'24-48.7%'25+16.7%YTD+98.8%

Money in ▸Pharma (Lilly · Jazz · royalties)●Revenue $75.1Milestones · royalties (104 programs)◐

AbCellera Biologics2025 revenue ~$33.7M, $700M liquidity

▸ Money outWet lab · sequencing · clinical (undisclosed)○

Financials & Segments

Total revenue · 2025 revenue ~$33.7M, $700M liquidity
Customer concentration · 104 programs; Lilly, Jazz.
Segments · Partnerships/milestones/royalties · Own pipeline

Revenue from

Pharma (Lilly · Jazz · royalties) High confidence· Revenue $75.1 · FY2025 · AbCellera FY2025 revenue ($27M partnered + $48M licensing/royalties)
Partnerships with Eli Lilly, Jazz and others, with upfronts, milestones and royalties (Jazz $56M upfront).
Confirms KO TheBio Published Jun 18, 2026: Jazz to develop next-generation TCE multispecific antibodies with Canada's AbCellera
Confirms EN AbCellera IR Published Feb 26, 2026: AbCellera Reports Full Year 2025 Business Results
Confirms EN SEC/StockTitan Published Feb 1, 2026: AbCellera 10-K (pipeline, $700M, royalties)
Confirms EN SEC EDGAR (AbCellera 10-K) Published Feb 27, 2025: AbCellera Biologics Inc. Form 10-K FY2024
Confirms EN Investing.com Published Jan 1, 2025: Jazz-AbCellera cancer-antibody partnership ($56M upfront)
Confirms EN AbCellera IR Published Jul 31, 2024: AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
Milestones · royalties (104 programs) Medium confidence
Downstream milestones and royalties from 104 partner programs.
Confirms EN SEC/StockTitan Published Feb 1, 2026: AbCellera 10-K (pipeline, $700M, royalties)
Confirms EN SEC EDGAR (AbCellera 10-K) Published Feb 27, 2025: AbCellera Biologics Inc. Form 10-K FY2024

Pays to

Wet lab · sequencing · clinical (undisclosed) Low confidence
Single-cell screening, wet-lab and clinical work.
Confirms EN SEC/StockTitan Published Feb 1, 2026: AbCellera 10-K (pipeline, $700M, royalties)

Analyst ratings

Consensus: Buy 3 · Hold 0 · Sell 0 · Avg. target $9 · Price $6.8 (07-10) · Upside +32%

Broker	Rating	Target	Published
JonesTrading · Debanjana Chatterjee	Buy	$13	Jun 26, 2026	Report ↗
BMO Capital Markets · Evan Seigerman	Outperform	$7	Jun 18, 2026	Report ↗
Stifel Nicolaus · Stephen Willey	Buy	$8	May 12, 2026	Report ↗

After strong ABCL635 Phase 1 data, Stifel and JonesTrading led a wave of target hikes; coverage is now uniformly Buy with an average target near $10.5.

Analyses covering this node

The application is still a story, the infrastructure demand is already measured: techbio as the first case Jun 23, 2026

← All companiesMarkdown · JSON